undamentalytics Newsletter
Sign in

Sarepta Therapeutics, Inc. cash flow statement

In fiscal 2025, Sarepta Therapeutics, Inc.'s operations generated −$205m of cash; it spent $102m on capital projects, leaving free cash flow of −$307m. It returned $25.0m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−129−149−246−232−389−456107−443−325−501−206−205111
Depreciation and amortisation4568122527384244384545
Stock-based pay20323030507910811423318318412399
Capital spending25351261608238317613710229
Free cash flow−154−153−251−244−450−51625−482−356−577−343−30782
Free cash flow after stock pay−174−185−281−274−500−595−83−596−589−760−527−431−17
Share buybacks—————————0025—
Shares issued95120365354513365312000020—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MRNA vs SRPTALKS vs SRPTHALO vs SRPT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sarepta Therapeutics, Inc.